In-line hydraulic crimp tool

Abstract

A crimp tool having jaw members joined in a tongue-in-groove connection held in place by a locking pin. Each jaw member being tapered and including weight reducing pockets defined in respective sidewalls. Each jaw member includes a locking tab on an outside edge that mates with a respective locking tab opening in the neck of the tool. When the locking pin is removed, the jaws of the tool separate and rotate away from one another until their respective locking tabs engage their respective locking tab opening, thereby holding the opened jaws in the neck of the tool.

Description

IN-LINE HYDRAULIC CRIMP TOOL CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the right of priority under 35 U.S.C. 119(e) to U.S. Provisional Application No. 62 / 330,598, filed on May 2, 2016. FIELD OF THE INVENTION

[0002] The present invention relates to cooperating jaws and hydraulic tools having cooperating jaws. More particularly, the present invention relates to hydraulic, hand-held crimp tools and jaw heads for crimp tools. BACKGROUND

[0003] Hand-held hydraulic tools are well known in the art. These tools use cooperating jaws that are hydraulically pressed together with great force to crimp materials. These tools may be battery-powered to allow mobility and portability for the user. These tools typically employ a locking pin that holds the jaws together for the crimping operation. The locking pin is removed to release the jaws.

[0004] Prior art crimping tools illustrative of the typical features, controls, and configurations are disclosed in U.S. Patents 7,216,523; 7,409,846; 7,434,441; 8,336,362 to Frenken, which may be reviewed for further detail. ~ 1 ~

[0005] The present inventor recognized certain perceived drawbacks with prior art hydraulic crimp tools and jaws for such crimp tools. Specifically, the inventor recognized that prior art crimp tools use hermaphroditic jaws, much like common scissors, which was perceived to result in uneven force being applied during crimping. Additionally, the present inventor recognized that inherent tolerances systemic in the bulk manufacturing of hermaphroditic jaws may adversely affect performance of the jaws in operation.

[0006] The present inventor also perceived a drawback with many prior art crimp tools in that they are difficult to manipulate by the user for various reasons. For example, as will be appreciated by one of ordinary skill in the art, when the locking pin for the jaws is removed, the jaws separate and may fall out of the tool, adding to the complexity of using the tool and interchangeable jaws / heads. The present inventor also recognized that the weight of crimp tools adversely affects the usability of these tools, as true with any tool carrying unnecessary weight. Additionally, the present inventor perceived a drawback in the casting process of hermaphroditic jaws in that there could be casting imperfections in the jaws due to uneven cooling of the metal with certain casting techniques.

[0007] As perceived by the present inventor, the foregoing highlights some of the possible problems and drawbacks with conventional hydraulic crimp tools and their jaws. Furthermore, the foregoing highlight's the present inventor's recognition of the long-felt, yet unresolved need in the art for a lighter tool and / or a tool with features that aid a user's ability to manipulate the tool without losing efficacy. In addition, the foregoing highlights the inventor's recognition of a need in the art for jaws that do not have the drawbacks of hermaphroditic jaws in manufacturing, use, and interchangeability. SUMMARY

[0008] Various embodiments of various permutations of the features and advantages of the present invention overcome various of the aforementioned and other disadvantages associated with prior art crimp tools and jaws. The present invention is based, in part, on the discovery that modifying the jaws of a crimping tool can aid the usability of the tool. Various objects of some embodiments of the invention are based, in part, on the discovery that predetermined placement of tabs on the jaws and tab notches on the tool neck can control the positioning on the jaws in an advantageous position. Other objects of various embodiments of the present invention are based, in part, on the discovery that the jaws of a tool can be tapered to reduce the weight of the tool without compromising crimping ability while also possibly removing weakness attributable to the typical prior art casting process. Further, pockets of material can be removed to reduce the weight without sacrificing strength and allowing the jaws to handle stress in a more uniform manner across the operative area of the jaws. Still other objects of other embodiments of the present invention are based, in part, on the discovery that the use of a tongue-and-groove arrangement of the jaws may be advantageous over hermaphaditic jaws. And still other objects of various embodiments of the present invention are based, in part, on the discovery that the provision of a bushing or sleeve for the locking pin bore to hold the jaws together after removal of the locking pin and for facilitating ease of entry and removal of the locking pin.

[0009] As discussed herein, the present inventor conceived of a tongue-and- groove arrangement of the jaws of a crimping tool to ensure the forces acting on the jaws during operation and use are symmetrical. The present inventor also conceived of the use of a sleeve or bushing in the locking pin opening to hold the tool jaws in place when the locking pin is removed as well as provide a smooth, uninterrupted surface for ease of inserting and removing the locking pin.

[0010] The present inventor also conceived of the use of tabs at the back end of the jaws to serve as stops to hold the jaws open. Preferably, the neck of the tool includes tab slots for receiving the tabs and holding the jaws in a desired position. Preferably, the tabs and notches are positioned to align the pivot hole with the jaw release pin to allow the rollers to contact the cam surfaces of the jaws.

[0011] The present inventor also conceived of ways to reduce the weight of the tool without compromising the strength of the tool. The present inventor conceived of improvements in the shape of the tool's jaws to maximize strength, reduce imperfections during casting, and at the same time reduce overall weight. The jaws can be tapered to reduce the weight of the tool without compromising crimping ability while also possibly removing weakness attributable to the typical prior art casting process. Further, pockets of material can be removed to reduce the weight without sacrificing strength and also providing the benefit of allowing the jaws to handle stress in a more uniform manner across the operative area of the jaws.

[0012] The various advantages aspects and features of the various embodiments of the invention described and claimed herein should become evident to a person of ordinary skill in the art given the following enabling description and drawings. The aspects and features disclosed herein believed to be novel and other elements characteristic of the various embodiments of the invention are set forth with particularity in the appended claims. The drawings are for illustration purposes only and are not drawn to scale unless otherwise indicated. The drawings are not intended to limit the scope of the invention despite depicting a presently preferred embodiment of the invention. The following enabling disclosure is directed to one of ordinary sill in the art and presupposes that those aspects of the invention within the ability of the ordinarily skilled artisan are understood and appreciated.

[0013] As used in this application, the terms "front," "rear," "upper," "lower," "upwardly," "downwardly," and other orientational descriptors are intended to facilitate the description of the exemplary embodiment described herein, and are not intended to limit the structure of the exemplary embodiments or limit the claims to any particular position or orientation. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] The advantageous aspects and features of various exemplary embodiments will be more apparent from the description of those exemplary embodiments taken with reference to the accompanying drawings, in which:

[0015] FIG. 1 is a side view of a battery-powered crimp tool embodiment according to various aspects of the present invention.

[0016] FIG. 2 is side view of the jaws of the crimp tool of FIG. 1 in the open position.

[0017] FIG. 3A is a cross-sectional view of the jaws of an embodiment of the present invention.

[0018] FIG. 3B is a cross-sectional top view of the jaws of FIG. 3A taken along line <com:Math><semantics>A−A<annotation encoding="application / x-tex">A-A< / annotation>< / semantics>< / com:Math>.

[0019] FIG. 4 is a perspective view of the jaws of an embodiment of the present invention shown in isolation.

[0020] FIG. 5 is a perspective view of the jaws and neck of an embodiment of a crimp tool of the present invention.

[0021] FIG. 6 is a front elevated perspective view of the jaws and neck of FIG. 5.

[0022] FIG. 7A is a side view of the jaws of an embodiment of the present invention.

[0023] FIG. 7B is a cross sectional view of the jaws of FIG. 7A taken along line B- B.

[0024] FIG. 8A is a side view in partial cross section of a neck and jaws of an embodiment of a crimp tool of the present invention.

[0025] FIG. 8B is an enlarged view of the portion of FIG. 8A encircled by the dotted line C.

[0026] FIG. 9A is a top view of the jaws and neck of a crimp tool according to an embodiment of the invention receiving a locking pin.

[0027] FIG. 9B is a sided view of the jaws and neck depicted in FIG. 9A

[0028] FIG. 9C is a cross-section of FIG. 9B taken along line H-H.

[0029] FIG. 9D is an enlarged view of the portion of FIG. 9B encircled by the dotted line F.

[0030] FIG. 10 is a side view of jaws of an embodiment of the invention opening after the locking pin is removed.

[0031] FIG. 11A-D is a top view of a wobble plate assembly according to an embodiment of the invention.

[0032] FIG. 12A-D is a cross-sectional side view of the wobble plate assembly of FIG.11A-D taken along lines A-A, B-B, C-C, and D-D, respectively.

[0033] FIG. 13A-D is close up of the wobble plate assembly of FIG. 12A-D of the features shown in circles A, B, C, and D, respectively.

[0034] FIG. 14 is a perspective view of a wobble plate assembly according to an embodiment of the invention. DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0035] While the present invention will be shown and described in connection with a battery-powered, hand-held crimp tool, one of ordinary skill in the art armed with the present application will readily appreciate that the inventive concepts and aspects of the invention may be implemented in a wide variety of tools, fields, and uses. The present invention should not be deemed to be limited to the embodiments that are described herein.

[0036] As shown in FIG. 1, a battery-powered crimp tool 100 includes a battery pack 101, a handle portion 102 that houses the controls 103 and a hand grip 104, a neck portion 105, and a pair of cooperating jaw members 110A, 110B.

[0037] As best shown on Figures 2 and 3, each jaw member includes a curved pressing lever 111 having a front tip portion 112 and a back portion 113. The interior area of jaw lever defines one or more curved crimp surfaces 114, 115. In the depicted embodiment, the jaws include crimp grooves 114, 115. As will be appreciated by one of ordinary skill in the art, these crimp grooves are permanent grooves comprising two chambers and a flat surface on top. While any configuration is deemed within the scope of the present invention, the presently preferred configuration depicted in the Figures shows a first crimp groove of the standard "D3" size, and the second crimp groove is a "BG" type. Other configurations using the crimp grooves sized for operation as a cable cutter head or "o" groove.

[0038] The tips 112 of the jaws according to the depicted embodiment include die buttons 119 as commonly found on crimp jaws. The die buttons 119 are operatively associated with the rear crimp groove 115. As will be appreciated, the die buttons 119 include a head portions, a spring portion, and a nut portion, each separated by a respective neck portion. The die buttons 119 serve to allow releasable attachment of die members from a die set.. For example, a desired "W" sized die member(s) may be selected from a "W" die set and secured in the second crimp groove(s) 115 via the die button(s) 119.

[0039] The jaws 110A, 110B are connected to one another by the use of a locking pin 130 that passes through internal bores disposed on internal hubs of the jaws back portion 113. Disposed in the internal bores is a sleeve or bushing 140 (see Figure 3B). The sleeve not only holds the two jaw members 110A, 110B together, but also allows pivot pin 130 to slide on one continuous surface when installing the jaws, thereby providing easier installation. In other words, the pin 130 will not be held up or catch in the areas where the respective jaws meet which may be slightly offset or have gaps. Additional, the sleeve 140 keeps the jaw members 100A, 110B of the crimp head together for easier handling when the pivot pin 130 is removed as discussed below.

[0040] As best shown in Figures 4-6, the jaws 110A, 110B are configured to open and close relative to one another using a tongue-and-groove arrangement wherein the first jaw 110A includes a groove 175 that accepts a protruding tongue portion 170 of the interior area of the back portion 113B of the second jaw 110B. The tongue-and- groove arrangement allows the jaws 110A, 110B to pivot around pivot pin 130 and pivot open without the back ends 113A, 113B of the jaws 110A, 10B bumping into each other. The groove 175 provides a recess for the back "tongue" end 170 of the second jaw 110B to advance so the back ends 113A, 113B of the jaws 110A, 110B can be rotated towards and ultimately passed one another, providing clearance for the jaws to fully open.

[0041] Importantly, the tongue-and-groove configuration allows the section to keep the forces acting on the jaws symmetrical as well as reducing the stress, thereby allowing for a smaller, lighter weight design. Specifically, as will be appreciated by one of ordinary skill in the art, prior art jaws are designed as hermaphroditic pairs. As such, similar to a pair of ordinary scissors attempting to cut a piece of cardboard, the forces and tolerances lead to binding and bending and other problems from the asymmetric application of forces. With the tongue-and-groove configuration, all of the forces are symmetrically received. In addition, this configuration allows for tighter tolerances to further enhance performance of the mating jaws.

[0042] The lighter weight design is also achieved, at least in part, on some embodiments by the provision of one or more "pockets" 121A, 121B, or areas where the cross section is thinner in a desired shape. These pockets 121A, 121B not only serve as weight reduction pockets, but also are believed to be used in configuring jaws designed to absorb stress in a more uniform manner across the operative portions of the jaws. One of ordinary skill in the art armed with the present specification can design the pockets of any suitable size and shape depending on the material of construction and overall design of the jaws through routine experimentation in order to achieve one or more of the advantageous features of the weight reduction pockets.

[0043] In addition, as best shown in Figure 7, a lighter weight design is achieved by tapering at least the tip portions 112A, 112B of the jaws 110A, 110B. In a presently preferred embodiment (see Figure 7B), the tip portions 112A, B are tapered in a generally I-shaped configuration where the body tapers at an angle or preferably 6 degrees. The variable cross-section of the tip ends of the jaws reduces weight by only having material where it is needed. Additionally, as will be appreciated by one of ordinary skill in the art, the casting process is not only made easier by the tapered configuration, but also results in a superior product. Specifically, as will be appreciated, tapering the mold helps the flow of material for casting the jaws. The tapering allows the material to cool evenly from the edges inwardly, as opposed to cooling in patches in an untampered product. Without wishing to be bound by theory, the present inventor believes that tapering allows the flow rates and pressure of the process to be optimized to a point that the material does not start cooling before it spreads throughout the mold. This, in turn, facilitates the even cooling from the edges inward.

[0044] While a generally I-shaped configuration with 6 degree tapering is shown, one of ordinary skill in the art should appreciated that any suitable configuration that lessons the weight and / or eases manufacturing while not compromising strength should be understood to be within the scope of the invention. One of ordinary skill in the art should readily appreciate that during operation, the base of the jaw receives more stress so that area is preferably thicker. Tapering along the length of the operative area allows a jaw to be configured to ensure stress is more uniform across the jaw. One of ordinary skill in the art armed with the present application can configure a jaw with tapering and / or pockets through routine experimentation in a manner to achieve one or more of the advantageous features of receiving uniform stress and weight reduction based on the ultimate design and material of construction.

[0045] An additional advantageous feature of various embodiments of the invention is best shown in Figures 8-10. As discernable from the Figures, the back ends 113A, 113B of the jaws 110A, 110B include raised tabs 150A, 150B. These tabs 150A, 150B serve as stops providing multiple advantages. First, in some embodiments such as the one depicted, the respective stops 150A, 150B are preferably positioned to facilitate installation by allowing the jaws 110A, 110B to only open an amount that results in the pivot pin 130 being aligned with the inside of the sleeve 140. Thus, the problem of a user having to user their hand to hold the jaws in alignment is mitigated. A user can now allow the jaws to release and fall open as shown in Figures 8-10 leaving the jaws aligned.

[0046] Secondly, in some embodiments such as the one depicted, the tabs 150A, 150B are sized and configured to mate with a respective tab notch 155A, 155B provided on the neck (yoke) 105 of the tool 100. Preferably, when the tabs 150A, 150B fit into their respective notches 155A, 155B they align the pivot hole with the jaw release pin and a also allow the roller 190 (see Figure 8B) to come in contact with the cam surfaces 118A, 118B of the jaws 110A, 110B. Again, the alignment mitigates a common problem with prior art tools.

[0047] In addition, an added benefit is that when the tabs 150A, 150B lock into their respective tab notches 155A, 155A, the jaws 110A, 110B are preventing from falling out of the tool 100 when the locking pin130 is removed. Additionally, when the locking pin 130 is pulled, the jaw members 110A, 110B not only remain in the tool 100, but also spring tension from spring member 180 (see Figures 9B, D) on the back ends 113A, 113B of the jaws 110A, 110B, the two tabs 150A, 150B are held securely in the notches 155A, 155B. As will be appreciated, spring member 180 biases the jaws. Opposite ends of the spring are connected to opposing jaw members by connections accessed through spring pin holes 181A, 181B.

[0048] Furthermore, as best shown in Figure 10, even if the pin 130 is removed, since the sleeve 140 is present, the two jaw members 110A, 110B are held together. The jaws 110A, 110B may move slightly, but once the tabs 150A, 150B lock into their notches 155A, 155B, the jaws 110A, 110B are held in place. As will be appreciated by one of ordinary skill in the art armed with the present specification, user frustration from the unlocking of the jaws and them falling off the tool is a common problem that is overcome by one or more of the above described embodiments utilizing tab members.

[0049] Various embodiments of the present invention, such as the presently preferred embodiment depicted in the Figures, lend themselves to the provision of additional advantageous features. For example, the tool 100 may make use of a trigger lock 106 for added safety. The trigger lock would preferably require release for every crimping operation. Similarly, the tool 100 could use a planetary gear box 107 that would provide lower ratio / less torque and tangential forces which results in the need for fewer bearings.

[0050] A presently preferred embodiment of a hydraulic tool 100 exemplifying various features of the invention also includes the feature of a ball bearing 200 being disposed between the interface 250 of the pump 300 and the wobble plate 400. The operation and interaction of the pump 300 and wobble plate 400 in prior art hydraulic tools is well understood in the art and the details of which will not be discussed herein. The presently preferred embodiment modifies the prior art structure. As shown in Figures 11-14, the pumps 300 are spaced .800" apart in the hydraulic pump body (not shown), and likewise, the spherical pockets 450 in the wobble plate 400 are also machined .800" apart. However, since the wobble plate 400 is always constrained at an angle (4 degrees), at certain points in the rotation, the effective distance between the two spherical cutouts is less than the .800" pump distance. As will be appreciated by one of ordinary skill in the art, if the pump was directly contacting the wobble plate 400, this would cause a sliding motion in that interface.

[0051] As will be appreciated by one of ordinary skill in the art armed with the present specification, when a ball bearing 200 is placed between each of the pumps 300 and the wobble plate 400, one more degree of freedom is created and the ball 200 creates a rolling contact, which greatly improves the efficiency, especially at high rotational speed. As shown in the Figures, there are two contact points 650A, 650B, and as the wobble plate 400 moves through its cycle, the "axis" 500 changes in a conical pattern 600 (see Figure 14 depicting the conical pattern for illustrative purposes). The end result of this configuration is an improved and more efficient tool.

[0052] The foregoing embodiments and advantages are merely exemplary and are not to be construed as limiting the scope of the present invention. The description of an exemplary embodiment of the present invention is intended to be illustrative, and not to limit the scope of the present invention. Various modification, alternatives and variations will be apparent to those of ordinary skill in the art, and are intended to fall within the scope of the invention.

Claims

1. A compound having the structural Formula (I): [Image disponible dans le document PDF, Image available in the PDF document] or a pharmaceutically acceptable salt thereof, wherein: [Image disponible dans le document PDF, Image available in the PDF document] R e R_e is hydrogen, alkyl (C≤6) , or substituted alkyl (C≤6) ; Y 1 Y_1 is alkanediyl (C≤12) , alkenediyl (C≤12) , arenediyl (C≤12) , heteroarenediyl (C≤12) , heterocycloalkanediyl (C ≤ 12 \leq 12 ) , − - alkanediy l ( C ≤ 8 ) l_{(C \le 8)} − - heterocycloalkanediy l ( C ≤ 12 ) l_{(C \le 12)} , − - alkanediy l ( C ≤ 8 ) l_{(C \le 8)} − - heterocycloalkanediy l ( C ≤ 12 ) l_{(C \le 12)} − - alkanediy l ( C ≤ 8 ) l_{(C \le 8)} , − - alkane- d i y l ( C ≤ 8 ) diyl_{(C \le 8)} —heteroarenediy l ( C ≤ 12 ) l_{(C \le 12)} , − - alkanediyl ( C ≤ 8 ) _{(C \le 8)} − - heteroarene- d i y l ( C ≤ 12 ) diyl_{(C \le 12)} —alkanediy l ( C ≤ 8 ) l_{(C \le 8)} , or a substituted version of any of these groups; [Image disponible dans le document PDF, Image available in the PDF document] A is − N R a -NR_a , − S -S , or − O -O ; wherein: R a R_a is hydrogen, alkyl ( C ≤ 6 ) (C \le 6) , or substituted alkyl ( C ≤ 6 ) (C \le 6) , or, alternatively, R a R_a and one of R 3 or R 4 are taken together with the attached atoms to form alkanediyl ( C ≤ 8 ) (C \le 8) or substituted alkanediyl ( C ≤ 8 ) (C \le 8) ; R 1 R_1 is a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] / wherein: R 5 R_5 , R 6 R_6 , and R 2 R_2 are each independently hydrogen or alkyl (C \le 8) , -alkanediyl ( C ≤ 6 ) _{(C \le 6)} -NH 2 , -alkanediyl ( C ≤ 6 ) _{(C \le 6)} -alkylamino ( C ≤ 8 ) _{(C \le 8)} , − a l k a n e d i y l ( C ≤ 6 ) − d i a l k y l a m i n o ( C ≤ 12 ) -alkanediyl_{(C \le 6)}-dialkylamino_{(C \le 12)} , − a l k a n e d i y l ( C ≤ 6 ) − N R ′ R ″ -alkanediyl_{(C \le 6)}-NR'R'' , a substituted version of any of these groups, or − Z 3 A ″ R 8 -Z_3A''R_8 ; wherein: R' and R" are each independently hydrogen, alkyl ( C ≤ 8 ) (C \le 8) , substituted alkyl ( C ≤ 8 ) (C \le 8) , or − Z 2 A ′ R 7 -Z_2A'R_7 ; wherein: Z 2 Z_2 is alkanediyl (C≤6) or substituted alkanediyl (C≤6) ; [Image disponible dans le document PDF, Image available in the PDF document] R b R_b is hydrogen, alky l ( C ≤ 6 ) l_{(C \le 6)} , or substituted alky l ( C ≤ 6 ) l_{(C \le 6)} ; and R j R_j is hydrogen, halo, hydroxy, acyloxy (C \le 24) , or substituted acyloxy (C≤24) ; R 7 R_7 is alkyl (C6-24) , substituted alkyl (C6-24) , alkenyl (C6-24) , or substituted alkenyl (C6-24) ; Z 3 Z_3 is alkanediyl (C≤6) or substituted alkanediyl (C≤6) ; [Image disponible dans le document PDF, Image available in the PDF document] R 1 R_1 is hydrogen, alky l ( C ≤ 6 ) l_{(C \le 6)} , or substituted alky l ( C ≤ 6 ) l_{(C \le 6)} ; and R k R_k is hydrogen, halo, hydroxy, acyloxy (C \le 24) , or substituted acyloxy (C≤24) ; and R 8 is alkyl (C6-24) , substituted alkyl (C6-24) , alkenyl (C6-24) , or substituted alkenyl (C6-24) ; q is 1, 2, or 3; and r is 1, 2, 3, or 4; or alternatively, R 1 R_1 is a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Y 2 Y_2 is heterocycloalkanediyl (C≤12) or substituted heterocycloalkanediyl (C<12) ; R 9 R_9 , R 10 R_{10} , and R 11 R_{11} are each independently hydrogen, alkyl (C≤8) , substituted alkyl (C ≤ 8 \leq 8 ) , or − Z 4 A ‴ R 12 -Z_4A'''R_{12} ; wherein: Z 4 Z_4 is alkanediyl (C \le 6) or substituted alkanediyl (C \le 6) ; [Image disponible dans le document PDF, Image available in the PDF document] R 1 R_1 is hydrogen, alky l ( C ≤ 6 ) l_{(C \le 6)} , or substituted alky l ( C ≤ 6 ) l_{(C \le 6)} ; and R k R_k is hydrogen, halo, hydroxy, acyloxy (C\leq 24) , or substituted acyloxy (C≤24) ; and R 12 R_{12} is alkyl (C6-24) , substituted alkyl (C6-24) , alkenyl (C6-24) , or substituted alkenyl (C6-24) ; and x and y are each independently an integer that is 0, 1, 2, 3, or 4; R 3 R_3 and R 4 R_4 are each independently hydrogen, alkyl ( C ≤ 6 ) (C \le 6) , or substituted alkyl ( C ≤ 6 ) (C \le 6) , or, alternatively, one of R 3 or R 4 and R a are taken together with the attached atoms to form alkanediy l ( C ≤ 8 ) l_{(C \le 8)} or substituted alkanediy l ( C ≤ 8 ) l_{(C \le 8)} ; and m and p are each independently an integer that is 0, 1, 2, 3, 4, 5, or 6; provided that if X 1 X_1 is positively charged then Z 1 Z_1 is negatively charged, and if X 1 X_1 is negatively charged, then Z 1 Z_1 is positively charged.

2. The compound or pharmaceutically acceptable salt thereof according to claim 1, having structural Formula (II): [Image disponible dans le document PDF, Image available in the PDF document] (II), wherein: Z 2 Z_2 is alkanediyl (C≤4) or substituted alkanediyl (C≤4) ; Z 3 Z_3 is alkanediyl (C≤4) or substituted alkanediyl (C≤4) ; and Z 4 Z_4 is alkanediyl (C≤4) or substituted alkanediyl (C≤4) .

3. The compound or pharmaceutically acceptable salt thereof according to claim 2, having structural Formula (II): [Image disponible dans le document PDF, Image available in the PDF document] (II), wherein: 𝒀 1 \mathbf{Y}_1 is alkanediy l ( C ≤ 12 ) l_{(C \le 12)} , heterocycloalkanediy l ( C ≤ 12 ) l_{(C \le 12)} , − - alkanediy l ( C ≤ 8 ) l_{(C \le 8)} − - heterocycloalkanediy l ( C ≤ 12 ) l_{(C \le 12)} , − - alkanediy l ( C ≤ 8 ) l_{(C \le 8)} − - hetero- cycloalkanediyl ( C ≤ 12 ) (C \le 12) —alkanediyl ( C ≤ 8 ) (C \le 8) , or a substituted version of any of these groups; and [Image disponible dans le document PDF, Image available in the PDF document]4. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1-3, having the structural Formula (IIa): [Image disponible dans le document PDF, Image available in the PDF document] (IIa), wherein: Z 2 Z_2 is alkanediyl (C≤4) or substituted alkanediyl (C≤4) ; Z 3 Z_3 is alkanediyl (C≤4) or substituted alkanediyl (C≤4) ; Z 4 Z_4 is alkanediyl (C≤4) or substituted alkanediyl (C≤4) ; and n is an independently an integer that is 1, 2, 3, 4, 5, or 6.

5. The compound or pharmaceutically acceptable salt thereof according to claim 1, having structural Formula (IIc): [Image disponible dans le document PDF, Image available in the PDF document] (IIc), wherein: n is an integer that is 1 , 2 , 3 , 4 , 5 1, 2, 3, 4, 5 , or 6 6 .

6. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1-5, wherein R a is hydrogen.

7. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1-6, wherein R 3 R_3 is alky l ( C ≤ 8 ) l_{(C \le 8)} or substituted alky l ( C ≤ 8 ) l_{(C \le 8)} .

8. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1-7, wherein R 4 R_4 is alky l ( C ≤ 8 ) l_{(C \le 8)} or substituted alky l ( C ≤ 8 ) l_{(C \le 8)} .

9. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1-8, wherein m is 1 or 2.

10. The compound or pharmaceutically acceptable salt thereof according to claim 4 or 5, wherein n is 2 or 3.

11. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1-10, wherein p is 1, 2, or 3.

12. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1-11, wherein R 1 R_1 is a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Z 2 Z_2 is alkanediy l ( C < 4 ) l_{(C<4)} or substituted alkanediy l ( C < 4 ) l_{(C<4)} ; and Z 3 Z_3 is alkanediyl (C≤4) or substituted alkanediyl (C≤4) .

13. The compound or pharmaceutically acceptable salt thereof according to claim 12, wherein r is 1 or 2.

14. The compound or pharmaceutically acceptable salt thereof according to claim 12 or 13, wherein R 5 R_5 is alky l ( C ≤ 8 ) l_{(C \le 8)} or substituted alky l ( C ≤ 8 ) l_{(C \le 8)} .

15. The compound or pharmaceutically acceptable salt thereof according to claim 12 or 13, wherein R 5 R_5 is − Z 3 A ″ R 8 -Z_3A''R_8 ; wherein: Z 3 Z_3 of R 5 R_5 is alkanediyl (C≤4) or substituted alkanediyl (C≤4) ; and [Image disponible dans le document PDF, Image available in the PDF document]16. The compound or pharmaceutically acceptable salt thereof according to claim 15, wherein Z 3 Z_3 of R 5 R_5 is alkanediyl (C1-2) or substituted alkanediyl (C1-2) .

17. The compound or pharmaceutically acceptable salt thereof according to claim 15 or 16, wherein A'' of R 5 R_5 is − C H R k -CHR_k -.

18. The compound or pharmaceutically acceptable salt thereof according to claim 15 or 16, wherein A" of R 5 R_5 is − C ( O ) O − -C(O)O- .

19. The compound or pharmaceutically acceptable salt thereof according to any one of claims 15-18, wherein R k R_k of R 5 R_5 is hydroxy.

20. The compound or pharmaceutically acceptable salt thereof according to any one of claims 15-18, wherein R k R_k of R 5 R_5 is acyloxy (C≤24) or substituted acyloxy (C≤24) .

21. The compound or pharmaceutically acceptable salt thereof according to any one of claims 15-20, wherein R 8 R_8 of R 5 R_5 is alkyl (C6-24) or substituted alkyl (C6-24) .

22. The compound or pharmaceutically acceptable salt thereof according to any one of claims 15-20, wherein R 8 R_8 of R 5 R_5 is alkenyl (C6-24) or substituted alkenyl (C6-24) .

23. The compound or pharmaceutically acceptable salt thereof according to claim 12 or 13, wherein R 5 R_5 is − alkanediyl ( C ≤ 6 ) − NH 2 -\text{alkanediyl}_{(C \le 6)} - \text{NH}_2 , − alkanediyl ( C ≤ 6 ) − alkylamino ( C ≤ 8 ) -\text{alkanediyl}_{(C \le 6)} - \text{alkylamino}_{(C \le 8)} , − - alkanediy l ( C ≤ 6 ) l_{(C \le 6)} − - dialkylamino ( C ≤ 12 ) _{(C \le 12)} , or a substituted version of any of these groups.

24. The compound or pharmaceutically acceptable salt thereof according to claim 23, wherein R 5 R_5 is − - alkanediyl ( C ≤ 6 ) _{(C \le 6)} -alkylamin ( C ≤ 8 ) _{(C \le 8)} or a substituted version of this group.

25. The compound or pharmaceutically acceptable salt thereof according to any one of claims 12-24, wherein R 6 R_6 is alky l ( C ≤ 8 ) l_{(C \le 8)} or substituted alky l ( C ≤ 8 ) l_{(C \le 8)} .

26. The compound or pharmaceutically acceptable salt thereof according to any one of claims 12-24, wherein R 6 R_6 is − Z 3 A ″ R 8 -Z_3A''R_8 ; wherein: Z 3 Z_3 of R 6 R_6 is alkanediy l ( C ≤ 4 ) l_{(C \le 4)} or substituted alkanediy l ( C ≤ 4 ) l_{(C \le 4)} ; and [Image disponible dans le document PDF, Image available in the PDF document]27. The compound or pharmaceutically acceptable salt thereof according to claim 26, wherein Z 3 Z_3 of R 6 R_6 is alkanediyl (C1-2) or substituted alkanediyl (C1-2) .

28. The compound or pharmaceutically acceptable salt thereof according to claim 26 or 27, wherein A" of R 6 R_6 is − C H R k -CHR_k -.

29. The compound or pharmaceutically acceptable salt thereof according to claim 26 or 27, wherein A" of R 6 R_6 is − C ( O ) O − -C(O)O- .

30. The compound or pharmaceutically acceptable salt thereof according to any one of claims 26-29, wherein R k R_k of R 6 R_6 is hydroxy.

31. The compound or pharmaceutically acceptable salt thereof according to any one of claims 26-29, wherein R k R_k of R 6 R_6 is acyloxy (C≤24) or substituted acyloxy (C≤24) .

32. The compound or pharmaceutically acceptable salt thereof according to any one of claims 26-31, wherein R 8 R_8 of R 6 R_6 is alkyl (C6-24) or substituted alkyl (C6-24) .

33. The compound or pharmaceutically acceptable salt thereof according to any one of claims 26-31, wherein R 8 R_8 of R 6 R_6 is alkenyl (C6-24) or substituted alkenyl (C6-24) .

34. The compound or pharmaceutically acceptable salt thereof according to any one of claims 12-24, wherein R 6 R_6 is − a l k a n e d i y l ( C ≤ 6 ) − N H 2 -alkanediyl_{(C \le 6)}-NH_2 , − a l k a n e d i y l ( C ≤ 6 ) − a l k y l a m i n o ( C ≤ 8 ) -alkanediyl_{(C \le 6)}-alkylamino_{(C \le 8)} , − - alkanediy l ( C ≤ 6 ) l_{(C \le 6)} − - dialkylamino ( C ≤ 12 ) _{(C \le 12)} , or a substituted version of any of these groups.

35. The compound or pharmaceutically acceptable salt thereof of claim 34, wherein R 6 is − - alkanediy l ( C ≤ 6 ) l_{(C \le 6)} − - alkylamin o ( C ≤ 8 ) o_{(C \le 8)} or a substituted version of this group.

36. The compound or pharmaceutically acceptable salt thereof according to any one of claims 12-35, wherein R 2 R_2 is alky l ( C ≤ 8 ) l_{(C \le 8)} or substituted alky l ( C ≤ 8 ) l_{(C \le 8)} .

37. The compound or pharmaceutically acceptable salt thereof according to any one of claims 12-35, wherein R 2 R_2 is − Z 3 A ″ R 8 -Z_3A''R_8 ; wherein: Z 3 Z_3 of R 2 R_2 is alkanediy l ( C ≤ 4 ) l_{(C \le 4)} or substituted alkanediy l ( C ≤ 4 ) l_{(C \le 4)} ; and [Image disponible dans le document PDF, Image available in the PDF document]38. The compound or pharmaceutically acceptable salt thereof according to claim 37, wherein Z 3 Z_3 of R 2 R_2 is alkanediyl (C1-2) or substituted alkanediyl (C1-2) .

39. The compound or pharmaceutically acceptable salt thereof according to claim 37 or 38, wherein A" of R 2 R_2 is − C H R k -CHR_k -.

40. The compound or pharmaceutically acceptable salt thereof according to claim 37 or 38, wherein A" of R 2 R_2 is − C ( O ) O − -C(O)O- .

41. The compound or pharmaceutically acceptable salt thereof according to any one of claims 37-40, wherein R k R_k of R 2 R_2 is hydroxy.

42. The compound or pharmaceutically acceptable salt thereof according to any one of claims 37-40, wherein R k R_k of R 2 R_2 is acyloxy (C≤24) or substituted acyloxy (C≤24) .

43. The compound or pharmaceutically acceptable salt thereof according to any one of claims 37-42, wherein R 8 R_8 of R 2 R_2 is alky l ( C 6 − 24 ) l_{(C6-24)} or substituted alky l ( C 6 − 24 ) l_{(C6-24)} .

44. The compound or pharmaceutically acceptable salt thereof according to any one of claims 37-42, wherein R 8 R_8 of R 2 R_2 is alkenyl (C6-24) or substituted alkenyl (C6-24) .

45. The compound or pharmaceutically acceptable salt thereof according to any one of claims 12-35, wherein R 2 R_2 is − a l k a n e d i y l ( C ≤ 6 ) − N H 2 -alkanediyl_{(C \le 6)}-NH_2 , − a l k a n e d i y l ( C ≤ 6 ) − a l k y l a m i n o ( C ≤ 8 ) -alkanediyl_{(C \le 6)}-alkylamino_{(C \le 8)} , − - alkanediyl ( C ≤ 6 ) _{(C \le 6)} − - dialkylamino ( C ≤ 12 ) _{(C \le 12)} , or a substituted version of any of these groups.

46. The compound or pharmaceutically acceptable salt thereof of claim 45, wherein R 2 is − - alkanediyl ( C ≤ 6 ) _{(C \le 6)} − - alkylamino ( C ≤ 8 ) _{(C \le 8)} or a substituted version of this group.

47. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1-11, wherein R 1 R_1 is a group of the formula: [Image disponible dans le document PDF, Image available in the PDF document] wherein: Z 4 Z_4 is alkanediyl (C≤4) or substituted alkanediyl (C≤4) .

48. The compound or pharmaceutically acceptable salt thereof according to claim 47, wherein Y 2 Y_2 is heterocycloalkanediyl (C≤12) .

49. The compound or pharmaceutically acceptable salt thereof according to claim 47 or 48, wherein R 9 R_9 is − Z 4 A ‴ R 12 -Z_4A'''R_{12} ; wherein: Z 4 Z_4 of R 9 R_9 is alkanediyl (C≤4) or substituted alkanediyl (C≤4) ; and [Image disponible dans le document PDF, Image available in the PDF document]50. The compound or pharmaceutically acceptable salt thereof according to claim 49, wherein Z 4 Z_4 of R 9 R_9 is alkanediyl (C1-2) or substituted alkanediyl (C1-2) .

51. The compound or pharmaceutically acceptable salt thereof according to claim 49 or 50, wherein A''' of R 9 R_9 is − C H R k -CHR_k -.

52. The compound or pharmaceutically acceptable salt thereof according to claim 49 or 50, wherein A''' of R 9 is − C ( O ) O − -C(O)O- .

53. The compound or pharmaceutically acceptable salt thereof according to any one of claims 49-52, wherein R k R_k of R 9 R_9 is hydroxy.

54. The compound or pharmaceutically acceptable salt thereof according to any one of claims 49-52, wherein R k R_k of R 9 R_9 is acyloxy (C \le 24) or substituted acyloxy (C \le 24) .

55. The compound or pharmaceutically acceptable salt thereof according to any one of claims 49-54, wherein R 12 R_{12} of R 9 R_9 is alkyl (C6-24) or substituted alkyl (C6-24) .

56. The compound or pharmaceutically acceptable salt thereof according to any one of claims 49-54, wherein R 12 R_{12} of R 9 R_9 is alkenyl (C6-24) or substituted alkenyl (C6-24) .

57. The compound or pharmaceutically acceptable salt thereof according to any one of claims 47-56, wherein R 10 R_{10} is − Z 4 A ‴ R 12 -Z_4A'''R_{12} ; wherein: Z 4 Z_4 of R 10 R_{10} is alkanediy l ( C ≤ 4 ) l_{(C \le 4)} or substituted alkanediy l ( C ≤ 4 ) l_{(C \le 4)} ; and [Image disponible dans le document PDF, Image available in the PDF document]58. The compound or pharmaceutically acceptable salt thereof according to claim 57, wherein Z 4 Z_4 of R 10 R_{10} is alkanediyl (C1-2) or substituted alkanediyl (C1-2) .

59. The compound or pharmaceutically acceptable salt thereof according to claim 57 or 58, wherein A''' of R 10 R_{10} is − C H R k − -CHR_k- .

60. The compound or pharmaceutically acceptable salt thereof according to claim 57 or 58, wherein A''' of R 10 R_{10} is − C ( O ) O − -C(O)O- .

61. The compound or pharmaceutically acceptable salt thereof according to any one of claims 57-59, wherein R k R_k of R 10 R_{10} is hydroxy.

62. The compound or pharmaceutically acceptable salt thereof according to any one of claims 57-59, wherein R k R_k of R 10 R_{10} is a c y l o x y ( C ≤ 24 ) acyloxy_{(C \le 24)} or substituted a c y l o x y ( C ≤ 24 ) acyloxy_{(C \le 24)} .

63. The compound or pharmaceutically acceptable salt thereof according to any one of claims 57-62, wherein R 12 R_{12} of R 10 R_{10} is alkyl (C6-24) or substituted alkyl (C6-24) .

64. The compound or pharmaceutically acceptable salt thereof according to any one of claims 57-62, wherein R 12 R_{12} of R 10 R_{10} is alkenyl (C6-24) or substituted alkenyl (C6-24) .

65. The compound or pharmaceutically acceptable salt thereof according to any one of claims 47-64, wherein R 11 R_{11} is − Z 4 A ‴ R 12 -Z_4A'''R_{12} ; wherein: Z 4 Z_4 of R 11 R_{11} is alkanediy l ( C ≤ 4 ) l_{(C \le 4)} or substituted alkanediy l ( C ≤ 4 ) l_{(C \le 4)} ; and [Image disponible dans le document PDF, Image available in the PDF document]66. The compound or pharmaceutically acceptable salt thereof according to claim 65, wherein Z 4 Z_4 of R 11 R_{11} is alkanediyl (C1-2) or substituted alkanediyl (C1-2) .

67. The compound or pharmaceutically acceptable salt thereof according to claim 65 or 66, wherein A''' of R 11 R_{11} is − C H R k − -CHR_k- .

68. The compound or pharmaceutically acceptable salt thereof according to claim 65 or 66, wherein A''' of R 11 R_{11} is − C ( O ) O − -C(O)O- .

69. The compound or pharmaceutically acceptable salt thereof according to any one of claims 65-68, wherein R k R_k of R 11 R_{11} is hydroxy.

70. The compound or pharmaceutically acceptable salt thereof according to any one of claims 65-68, wherein R k R_k of R 11 R_{11} is a c y l o x y ( C ≤ 24 ) acyloxy_{(C \le 24)} or substituted a c y l o x y ( C ≤ 24 ) acyloxy_{(C \le 24)} .

71. The compound or pharmaceutically acceptable salt thereof according to any one of claims 65-70, wherein R 12 R_{12} of R 11 R_{11} is alkyl (C6-24) or substituted alkyl (C6-24) .

72. The compound or pharmaceutically acceptable salt thereof according to any one of claims 65-70, wherein R 12 R_{12} of R 11 R_{11} is alkenyl (C6-24) or substituted alkenyl (C6-24) .

73. A compound or pharmaceutically acceptable salts thereof having a structural formula [Image disponible dans le document PDF, Image available in the PDF document] selected from the group consisting of: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] , wherein R is selected from the group consisting of octyl, decyl, dodecyl, tetradecyl, hexadecyl, and octadecyl. inereof hav.

74. A compound or pharmaceutically acceptable salts thereof having a structural formula → N O R \stackrel{N}{\longrightarrow} O_R selected from the group consisting of: , [Image disponible dans le document PDF, Image available in the PDF document] consisting of octyl, decyl, dodecyl, tetradecyl, hexadecyl, and octadecyl.

75. A compound or pharmaceutically acceptable salts thereof selected from the group [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] , and [Image disponible dans le document PDF, Image available in the PDF document]76. A composition comprising: (A) a compound according to any one of claims 1-75; and (B) a therapeutic agent.

77. The composition according to claim 76, wherein the therapeutic agent is a nucleic acid.

78. The composition according to claim 77, wherein the nucleic acid is a therapeutic nucleic acid.

79. The composition according to claim 77, wherein the nucleic acid is a siRNA.

80. The composition according to claim 77, wherein the nucleic acid is a tRNA.

81. The composition according to claim 77, wherein the nucleic acid is an mRNA.

82. The composition according to claim 77, wherein the nucleic acid is a sgRNA.

83. The composition according to any one of claims 76-82, wherein the composition further comprises a steroid or steroid derivative.

84. The composition according to any one of claims 76-83, wherein the composition further comprises a phospholipid.

85. The composition according to any one of claims 76-84, wherein the composition further comprises a PEG conjugated lipid.

86. The composition according to claim 85, wherein the PEG conjugated lipid is: [Image disponible dans le document PDF, Image available in the PDF document] wherein: n 1 n_1 is an integer from 1 to 250; and n 2 and n 3 are each independently an integer from 5 to 23.

87. The composition according to any one of claims 77-86, wherein the composition comprises a mole ratio of the compound to the nucleic acid from about 5:1 to about 1000:1.

88. The composition according to any one of claims 83-87, wherein the composition comprises a ratio of the compound to the steroid or steroid derivative from about 1:1 to about 20:1.

89. The composition according to any one of claims 84-88, wherein the composition comprises a ratio of the compound to the phospholipid is from about 1:1 to about 9:1.

90. The composition according to any one of claims 85-89, wherein the composition comprises a ratio of the compound to the PEG conjugated lipid is from about 2.5:1 to about 100:1.

91. The composition according to any one of claims 85-90, wherein the composition comprises a ratio of the compound to the steroid or steroid derivative to the phospholipid to the PEG conjugated lipid is from about 25:57:15:3 to about 75:19:5:1.

92. The composition according to any one of claims 76-91, further comprising a pharmaceutically acceptable carrier.

93. The composition according to claim 92, wherein the composition is formulated for aerosol, intravenous, intraperitoneal, subcutaneous, topical, or oral administration.

94. The composition according to claim 93, wherein the composition is formulated for injection.

95. Use of the compound or pharmaceutically acceptable salt thereof according to any one of claims 1-75 or the composition according to any one of claims 76-94 for the delivery of the therapeutic agent into a cell of a subject.

96. The use according to claim 95, wherein the cell is in vitro or ex vivo.

97. The use according to claim 95, wherein the cell is in vivo.

98. The use according to any one of claims 95-97, wherein the subject is human.

99. The use according to any one of claims 95-98, wherein the therapeutic agent is associated with a genetic disease.